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Abstract
Purpose The need of prophylactic central neck dissection
(PCND) in patients with papillary thyroid carcinoma (PTC)
is still controversial. The major restriction of PCND is the
potential complications. We undertook a retrospective
study to discuss its necessity in PTC patients.
Methods A total of 188 patients with PTC who underwent
total thyroidectomy and PCND were involved. In all of
these, central lymph nodes were pathologic examined.
Univariate and multivariate analyses were performed based
on tumor location and size, etc.
Results Overall, node metastases were found in 44.1 %
(83/188) of patients. Tumor size was the independent
positive predictor for lymph node metastasis, while gender,
age, tumor multifocality, tumor location, and capsular
infiltration were not independent predictors of central
lymph node metastases. Postoperative complications hap-
pened in 5.3 % (10/188) of patients, which 4.8 % (9/188)
had temporary hypocalcemia and 0 % (0/188) had perma-
nent hypocalcemia. Rates of temporary and permanent
recurrent laryngeal nerve injury were 0.5 % (1/188) and
0 % (0/188), respectively.
Conclusions PCND is recommended in all patients with
PTC.
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Introduction
Thyroid carcinoma is the most common endocrine malig-
nancy, which incidence increased in the last several dec-
ades. Papillary thyroid carcinoma (PTC) is the most
common histological subtype, accounting for more than
85 % of all cases. The prognosis of PTC is general good,
with 10-year survival rate exceeds 95 % and 20-year sur-
vival rate exceeds 93 % [1–5]. Despite its excellent out-
comes, studies have showed that recurrence is an important
factor increasing in morbidity and mortality, and cervical
lymph node metastasis is most important variable known to
increase the risk of local recurrence [6, 7].
It has been shown that cervical lymph node metastasis
was found in 20–90 % of patients who undertook cervical
lymph node dissection [8, 9]. Of theses, central lymph node
metastasis is most common [10, 11]. For now, routinely
performing a neck dissection in patients with clinically
positive neck lymph nodes (cN?) has been a consensus.
However, there is a controversy concerning the need and
indications for a neck dissection in PTC patients showing
clinically negative neck lymph nodes (cN0), which means
prophylactic central neck dissection (PCND) [12–16].
The present study was a retrospective analysis of patients
with cN0 PTC from the General Surgery department of Xin-
hua Hospital and from the Renji Hospital affiliated to
Shanghai Jiaotong University School of Medicine in the past
3 years. Univariate and multivariate analyses were performed
to assess the factors predicting for central lymph nodes
metastases. Results may provide clues on the necessity of
PCND and contribute to the improvement of PTC treatment.
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Patients and methods
Subjects were selected according to the following criteria:
(1) patients admitted for thyroid carcinoma in the General
Surgery Department of Xinhua Hospital or in the Renji
Hospital affiliated to Shanghai Jiao Tong University School
of Medicine; (2) previously untreated patients; (3) surgical
treatment was required for the primary tumor; (4) PTC
diagnosed based on frozen paraffin sections; (5) PCND
undertook in the same operating time after thyroidectomy;
(6) lymph node metastases was not found clinically or
radiologically prior to surgery (clinical N0/cN0); and (7)
complete medical records were available for data
extraction.
Table 2 Univariate analysis of central lymph node metastases
Central Lymph node metastasis P
? (%) - (%)
Gender
Female 65 42.5 88 57.5 0.3364
Male 18 51.4 17 48.6
Age at diagnosis
\45 43 51.8 40 48.2 0.0601
C45 40 38.1 65 61.9
Diseased lobe 1
Both 20 60.6 13 39.4 0.1096
Left 28 39.4 43 60.6
Isthmus 0 0.0 2 100.0
Right 35 42.7 47 57.3
Diseased lobe 2
Single 63 40.6 92 59.4 0.0360
Both 20 60.6 13 39.4
Tumor size
B1 cm 33 35.1 61 64.9 0.0392
[1 and B2 cm 41 53.9 35 46.1
[2 and B4 cm 8 47.1 9 52.9
[4 cm 1 100.0 0 0.0
Multifocality
No 57 39.6 87 60.4 0.0226
Yes 26 59.1 18 40.9
Capsular invasion
No 75 44.6 93 55.4 0.6926
Yes 8 40.0 12 60.0
Postoperative complications
No 78 43.8 100 56.2 0.4733
Yes 5 50.0 5 50.0
Tumor location
Up 9 45.0 11 55.0 0.8645
Up-Middle 3 33.3 6 66.7
Middle 30 40.0 45 60.0
Middle- Down 9 47.4 10 52.6
Down 6 31.6 13 68.4
Total 83 44.1 105 55.9
Table 1 Clinical and pathological characteristics of 188 patients with
PTC











Left and right 33 17.6
Tumor size*
B1 cm 94 50
[1 and B2 cm 76 40.4
[2 and B4 cm 17 9.0























IV A 6 3.2
IV B 0 0.0
IV C 0 0.0
* Maximum measurement of tumor size
** Only in cases of solitary tumor located in left or right lobe
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Following data were extracted from the medical records:
gender, age at diagnosis, tumor size, tumor location,
presence of local invasion, TNM classification, presence
of central lymph node metastases, and postoperative
complications.
TNM was assessed according to the 7th edition (2010)
of the thyroid cancer TNM staging system from AJCC
(American Joint Committee on Cancer)/UICC (Interna-
tional Federation of Cancer). The surgical procedure was
followed according to NCCN practice guidelines. To the
patients underwent total thyroidectomy we performed
bilateral PCND, and to the patients underwent lobectomy
the ipsilateral PCND was received.
Data collection was performed using Microsoft Excel
(Redmond, WA, USA). Statistical analyses were per-
formed using SAS 8.0 software (Cary, NC, USA). Stu-
dent’s t test was used to compare normally distributed
variables between groups. Non-normally distributed vari-
ables were analyzed using Wilcoxon’s rank test. Categor-
ical variables were analyzed using the v2 test or Fisher
exact test. Multivariate analyses were conducted using
unconditional logistic regression. Statistical significance
was assumed when P \ 0.05.
Results
A total of 188 patients were involved in the present study.
All cases were confirmed as PTC using frozen paraffin
sections. Table 1 shows patient demographics. For each
patient, an average of three lymph nodes were obtained
(range, 1–16, median = 3). Pathological examination
showed that central lymph node metastases were found in
83 patients (83/188, 44.1 %).
Postoperative complications happened in 10 patients
(10/188, 5.3 %), in which 9 (9/188, 4.8 %) had temporary
hypocalcemia and 0 (0/188, 0 %) had permanent hypo-
calcemia. Rates of temporary and permanent recurrent
laryngeal nerve injury were 0.5 % (1/188) and 0 % (0/188),
respectively.
Table 2 shows the results of univariate analyses
based on central lymph node metastasis. Results revealed
that large tumor size (P = 0.04), disease affecting both
lobes (P = 0.04), and multifocality (P = 0.02) were
significantly positively associated to central lymph node
metastasis.
Meanwhile, gender, age at diagnosis, tumor size, mul-
tifocality, tumor location, and capsular invasion were put in
the logistic regression model. Results show that tumor size
was independent predictive factor for central lymph node
metastasis (Table 3).
Discussion
There is controversy in the application of PCND to the
patients with PTC, which mainly focus on the balance of
the potential benefits and the postoperative complications.
The benefits of PCND have become more and more
clear. In our study, the positive nodes were found in 44.1 %
of patients of PTC. Statistic analysis showed that the larger
the tumor was, the more likely to find central lymph node
metastasis, with the incidence of 35.1, 53.9, 47.1, and
100.0 % in tumor size of less than 1, 1–2, 2–4 cm, and
lager than 4 cm, respectively. At the same time, tumor size
was also an independent predictive factor for central lymph
node metastases in cN0 PTC patients, with a positive
correlation (correlation coefficient b = 1.2031, P = 0.004,
OR = 3.330, 95 % CI = 1.474–7.525). These results
consist with most reports. Ito et al. [14] also showed a
positive correlation between tumor size and the incidence
of central lymph node metastases, with the incidence of
38.3, 59.2, 73.7, and 79.0 % in tumor size of less than 1,
1–2, 2–4 cm, and lager than 4 cm, respectively. Roh et al.
[12] using multivariate analyses reported that tumor size
C1 cm was an independent factor for ipsilateral central
lymph node metastases. Koo et al. [13] obtained the same
results: either ipsilateral or contralateral lymph node
metastases were more likely to occur in tumors [1 cm.
However, a study by Kutler et al. [17] showed that tumor
size had no significant impact on the presence of central
lymph node metastases (P = 0.18). Generally, most
researchers have had the consensus that the larger the
tumor is, the more metastases may occurred.
This study also showed that both thyroid lobes had
carcinoma would cause more nodal metastasis than one
lobe, and multifocality of tumor would lead to higher
incidence of metastasis than single tumor either.
As for the other factors such as patients’ age and gender,
our results showed no significant difference in nodal
metastasis. This consists with previously reported results
[13, 17]. It means the application of PCND should not
limited by patients age or gender.
Although not shown in this study, recent studies have
shown that lymph node metastasis is related to increasing
local recurrence and reducing survival rate. A large study
have reported that mortality of PTC patients with nodal
Table 3 Logistic regression analysis of central Lymph node
metastases
B SE P OR 95 % CI
Tumor size 1.2031 0.4159 0.0038 3.330 1.474–7.525
Constant 0.5720 1.4491 0.6930
SE standard error, OR odds ratio, CI confidence interval
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metastases was much greater than the patients without
metastases. Thus to the patients with PTC, the benefits
from PCND are obvious, the dissection can decrease local
recurrence and increase the patient survival [6].
Another important reason to have PCND is that there is
no other reliable method to verify central lymph node
metastasis, whether preoperative or intraoperative ultra-
sound or other methods are far from sufficient sensitivity to
verify the central lymph node metastasis [18]. Stulak et al.
[19] showed in their study that in total of 511 patients with
PTC, the clinical nodal negative patients were 476, in
which preoperative ultrasound detected positive central
lymph nodes in 10 patients (2.1 %) and positive cervical
lymph nodes in 70 patients (14.4 %). But the truth was, the
positive central lymph nodes were confirmed in 179 cases
(32.5 %) and positive cervical lymph node was found in 86
cases (15.6 %). Kouvaraki et al. [9] showed that in 161
patients with preoperative ultrasonography, the positive
central nodal incidence was 39.1 % (63/161), while the
final pathological examination was proved to be 73.3 %,
which implied false positive results in 2 (2/63) patients and
57 false negative results(57/98) of ultrasound examination.
Therefore, before other reliable authentication methods
arise, there is no better way to assess central lymph node
metastasis other than PCND.
Furthermore, the results of PCND can help patients get
clear staging after surgery, and subsequently take much
more precise treatment. Explicit postoperative staging of
patients with PTC can have following benefits of treatment:
(1) to assess the prognosis; (2) to guide postoperative
adjuvant therapy for individual programs, including 131I
therapy and TSH suppressive therapy, which can reduce
recurrence and mortality; (3) to determine the time and
frequency of follow-up, which high-risk patients require
intensive follow-up; (4) contribute to communication
between physicians of patient information; and (5) staging
system for clinical research can be used to assess the dif-
ferent groups of patients to different treatment [20, 21].
The main reason preventing us from taking PCND is the
potential postoperative complications. As the increase in
application of PCND, postoperative complications such as
hypocalcemia, recurrent laryngeal nerve injury may
increase [11, 22, 23] but as we have more experience, the
incidence has been dropped obviously in the resent years
[24–26]. Our study showed that the incidence of postop-
erative complications was 5.3 % (10/188); all of these were
transient and no permanent complications, which included
nine cases of hypocalcemia and one case of recurrent lar-
yngeal nerve injury. But to the PTC patients who under-
went recurrence, the reoperation for the treatment could be
a total disaster. The disorders of structure would lead to
much more severe complications and result in poor prog-
nosis [27, 28].
In conclusion, the main reason stoping us taking PCND
is the potential complications, but the data mentioned
above have shown that after enough exercises, the inci-
dence could be reduced to just like without PCND. Besides
the high incidence of central lymph nodes metastasis in
patients with PTC, the application of PCND will reduce
tumor recurrence and patient’s mortality, and the patho-
logical results of PCND will promote the follow-up treat-
ment, we recommend PCND to all patients with PTC. But
considering the good outcome of PTC and with the purpose
to reduce complications as much as possible, we suggest
that the prevention of complications should always be put
to top priority in operation, which means during the surgery
preference should be given to the removal of parts not
leading to complications. After all, our purpose is to give
patient better prognosis. In general, we recommend a
compromised PCND to all patients with PTC, which means
the PCND should compromise with the priority of low
complication.
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